As glucagon-like peptide 1 (GLP-1) receptor agonist use becomes more prevalent, patients are using them for new indications — and at new dosages. Say hello to microdosing, or taking doses lower than the recommended therapeutic amount, for various reasons: Weight maintenance, metabolic health improvements, anti-inflammation and anti-autoimmune effects, fewer side effects, and lower costs. Advocates … Read more
Consumption of sugary drinks is linked to 9.8% of new cases of type 2 diabetes (T2D) annually, contributing to approximately 2.2 million cases worldwide. These beverages are also linked to 1.2 million new cardiovascular disease (CVD) cases each year, or 3.1% of the global total, according to a study published in Nature Medicine. The researchers analyzed … Read more
Women with premature and early menopause had a higher risk of developing type 2 diabetes (T2D), according to data published in JAMA Network Open.1 Researchers’ findings suggest early detections of menopause may inform the management of T2D in women. “Although the prevalence of T2D in young adults is higher in men, it increases in women … Read more
Patients with type 2 diabetes (T2D) exhibited similar outcomes when prescribed either empagliflozin or dapagliflozin for treating chronic kidney disease (CKD), according to data published in JAMA Internal Medicine.1 With study results showing neither drug is more effective than the other within this population, researchers agree with the current practice of not recommending either drug … Read more
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) — Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its industry-leading obesity test. Digbi Health is introducing innovative components to personalize nutritional and pharmacotherapy support to ensure everyone receives the right care based on their biology and lifestyle. … Read more
Archyde Empagliflozin and Weight Loss: A Promising First-Line Treatment for Diabetes and Prediabetes Table of Contents 1. Empagliflozin and Weight Loss: A Promising First-Line Treatment for Diabetes and Prediabetes 2. Understanding the Study 3. Key Findings 4. What This Means for patients 5. Limitations and Future Directions 6. Conclusion 7. How Does Empagliflozin Contribute to … Read more
Preterm Birth at 50: Higher Blood Pressure, Lower Cardiovascular Events New research sheds light on the long-term health outcomes of individuals born preterm, revealing a complex interplay of risks and benefits compared to those born at term. A landmark study followed participants from the Auckland Steroid Trial, the first randomized trial of antenatal corticosteroids for … Read more
TOPLINE: Adults aged 50 years who were born preterm have a higher risk for hypertension but lower risk for cardiovascular events than those born at term, with similar risks for diabetes, prediabetes, and dyslipidemia between groups. METHODOLOGY: The researchers conducted a prospective cohort study of the Auckland Steroid Trial — the first randomized trial of … Read more
Estimation of cardiovascular risk (CVR) in individuals living with type 1 diabetes (T1D) was a key topic presented by Sophie Borot, MD, from Besançon University Hospital, Besançon, France, at the 40th congress of the French Society of Endocrinology. Borot highlighted the complexities of this subject, outlining several factors that contribute to its challenges. A Heterogeneous … Read more